{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T20:49:31Z","timestamp":1790887771017,"version":"4.1.0"},"reference-count":39,"publisher":"American Society for Microbiology","issue":"6","license":[{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2013,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Safe, effective concomitant treatment regimens for tuberculosis (TB) and HIV infection are urgently needed. Bedaquiline (BDQ) is a promising new anti-TB drug, and efavirenz (EFV) is a commonly used antiretroviral. Due to EFV's induction of cytochrome P450 3A4, the metabolic enzyme responsible for BDQ biotransformation, the drugs are expected to interact. Based on data from a phase I, single-dose pharmacokinetic study, a nonlinear mixed-effects model characterizing BDQ pharmacokinetics and interaction with multiple-dose EFV was developed. BDQ pharmacokinetics were best described by a 3-compartment disposition model with absorption through a dynamic transit compartment model. Metabolites M2 and M3 were described by 2-compartment models with clearance of BDQ and M2, respectively, as input. Impact of induction was described as an instantaneous change in clearance 1 week after initialization of EFV treatment and estimated for all compounds. The model predicts average steady-state concentrations of BDQ and M2 to be reduced by 52% (relative standard error [RSE], 3.7%) with chronic coadministration. A range of models with alternative structural assumptions regarding onset of induction effect and fraction metabolized resulted in similar estimates of the typical reduction and did not offer a markedly better fit to data. Simulations to investigate alternative regimens mitigating the estimated interaction effect were performed. The results suggest that simple adjustments of the standard regimen during EFV coadministration can prevent reduced exposure to BDQ without increasing exposures to M2. However, exposure to M3 would increase. Evaluation in clinical trials of adjusted regimens is necessary to ensure appropriate dosing for HIV-infected TB patients on an EFV-based regimen.<\/jats:p>","DOI":"10.1128\/aac.00191-13","type":"journal-article","created":{"date-parts":[[2013,4,10]],"date-time":"2013-04-10T01:21:41Z","timestamp":1365556901000},"page":"2780-2787","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":87,"title":["Model-Based Estimates of the Effects of Efavirenz on Bedaquiline Pharmacokinetics and Suggested Dose Adjustments for Patients Coinfected with HIV and Tuberculosis"],"prefix":"10.1128","volume":"57","author":[{"given":"Elin M.","family":"Svensson","sequence":"first","affiliation":[{"name":"Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Aweeka","sequence":"additional","affiliation":[{"name":"University of California, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong-Gun","family":"Park","sequence":"additional","affiliation":[{"name":"Harvard School of Public Health, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Marzan","sequence":"additional","affiliation":[{"name":"University of California, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly E.","family":"Dooley","sequence":"additional","affiliation":[{"name":"Johns Hopkins University School of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mats O.","family":"Karlsson","sequence":"additional","affiliation":[{"name":"Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","volume-title":"Global tuberculosis report 2012","author":"World Health Organization","year":"2012","unstructured":"World Health Organization. 2012. Global tuberculosis report 2012. World Health Organization, Geneva, Switzerland."},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00042-10"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1013607"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1086\/518655"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio884"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1106753"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00181-07"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01611-09"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201103-0397OC"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0017556"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00978-10"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0808427"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06126-11"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01204-07"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00766-06"},{"key":"e_1_3_3_17_2","volume-title":"Briefing document, TMC207 (bedaquiline), treatment of patients with MDR-TB, NDA 204\u2013384","author":"Janssen Pharmaceutical Companies","year":"2012","unstructured":"Janssen Pharmaceutical Companies. 28 November 2012. Briefing document, TMC207 (bedaquiline), treatment of patients with MDR-TB, NDA 204\u2013384. Janssen Pharmaceutical Companies, Titusville, NJ."},{"key":"e_1_3_3_18_2","volume-title":"Proc. 38th World Conf. Lung Health","author":"Mesens N","year":"2007","unstructured":"MesensN VerbeeckJ RouanM. 2007. Elucidating the role of M2 in the preclinical safety profile of TMC207, abstr PS-71291\u201311. Proc. 38th World Conf. Lung Health, Cape Town, South Africa."},{"key":"e_1_3_3_19_2","volume-title":"FDA Anti-Infective Drugs Advisory Committee Meeting","author":"FDA Office of Antimicrobial Products","year":"2012","unstructured":"FDA Office of Antimicrobial Products. 28 November 2012. Briefing package, NDA 204-384, Sirturo (bedaquiline 100-mg tablets), for the treatment of adults (\u226518 years) as part of combination therapy of pulmonary multi-drug-resistant tuberculosis (MDRTB). FDA Anti-Infective Drugs Advisory Committee Meeting. FDA Office of Antimicrobial Products, Silver Spring, MD."},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3182410503"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1086\/597125"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-007-9066-0"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01537-08"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4419-9485-1"},{"key":"e_1_3_3_25_2","volume-title":"NONMEM user's guides (1989\u20132010)","author":"Beal S","year":"2010","unstructured":"BealS SheinerLB BoeckmannA BauerRJ. 2010. NONMEM user's guides (1989\u20132010). Icon Development Solutions, Ellicott City, MD."},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmpb.2003.11.003"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmpb.2005.04.005"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-2607(98)00067-4"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmpb.2010.04.018"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00720-11"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00566-08"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00934-10"},{"key":"e_1_3_3_33_2","doi-asserted-by":"crossref","unstructured":"CrucianiG BaroniM BenedettiP GoracciL FortunaGL. 2013. Exposition and reactivity optimization to predict sites of metabolism in chemicals. Drug Discov. Today Technol. 10:e155\u2013e165. http:\/\/dx.doi.org\/10.1016\/j.ddtec.2012.11.001.","DOI":"10.1016\/j.ddtec.2012.11.001"},{"key":"e_1_3_3_34_2","article-title":"Modelling cytochrome p450 binding modes to predict P450 inhibition, metabolic stability and isoform selectivity","author":"Carosati E","unstructured":"CarosatiE. Modelling cytochrome p450 binding modes to predict P450 inhibition, metabolic stability and isoform selectivity. Drug Discov. Today Technol., in press.","journal-title":"Drug Discov. Today Technol"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1590\/S1806-37132008001100009"},{"key":"e_1_3_3_36_2","doi-asserted-by":"crossref","first-page":"202","DOI":"10.7883\/yoken.JJID.2008.202","article-title":"Serum zinc and albumin levels in pulmonary tuberculosis patients with and without HIV","volume":"61","author":"Ramakrishnan K","year":"2008","unstructured":"RamakrishnanK ShenbagarathaiR KavithaK UmaA BalasubramaniamR ThirumalaikolundusubramanianP. 2008. Serum zinc and albumin levels in pulmonary tuberculosis patients with and without HIV. Jpn. J. Infect. Dis. 61:202\u2013204.","journal-title":"Jpn. J. Infect. Dis"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1208\/ps040104"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05792-11"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01120-08"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1999.00090.x"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00191-13","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00191-13","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T16:43:34Z","timestamp":1715186614000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00191-13"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["10.1128\/AAC.00191-13"],"URL":"https:\/\/doi.org\/10.1128\/aac.00191-13","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6]]},"assertion":[{"value":"2013-01-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-04-03","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-05-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}